nach oben

Endocrine

Erschienen in:

01.06.2010 | Original Article

Monocyte chemoattractant protein-1 (MCP-1) 2518G/A gene polymorphism in Turkish type 2 diabetes patients with nephropathy

verfasst von: M. Karadeniz, M. Erdogan, Sevki Cetinkalp, A. Berdeli, Z. Eroglu, A. G. Ozgen

Erschienen in: Endocrine | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Tissue macrophage accumulation is thought to induce insulin resistance during obesity and stimulate the progression of diabetic nephropathy (DN). The objective of this study was to investigate genotypic and allelic frequencies of monocyte chemoattractant protein-1 (MCP-1) gene polymorphism in the healthy and patients with and without DN. The MCP-1 genotypes were determined in 43 patients with nephropathy and 43 without nephropathy and a control group of 105 healthy individuals. The genotype MCP-1 (−2518G/A) distribution did differ between the control group and the type 2 diabetic patients (P = 0.004). The frequency of the polymorphic G allele was also no similar for the group with type 2 diabetes as for the control group with 20.9 and 32.4%, respectively (P = 0.012). The AA genotype and A allele at MCP-1 −2518 was an independent risk factor for the progression of type 2 diabetes. In conclusion, MCP-1 AA genotype and A allele may play a specific role(s) in determining diabetic susceptibility, but do not seem to be important in the clinical manifestations of DN.

P. Iglesias, J.J. Diez, Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur. J. Endocrinol. 154(5), 613–621 (2006)CrossRefPubMed

C. Baylis, E.A. Atzpodien, G. Freshour et al., Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J. Pharmacol. Exp. Ther. 307(3), 854–860 (2003)CrossRefPubMed

P. Hovind, P. Rossing, L. Tarnow, U.M. Smidt, H.H. Parving, Progression of diabetic nephropathy. Kidney Int. 59, 702–709 (2001)CrossRefPubMed

B.I. Freedman, M. Bostrom, P. Daeihagh, D.W. Bowden, Genetic factors in diabetic nephropathy. Clin. J. Am. Soc. Nephrol. 2(6), 1306–1316 (2007)CrossRefPubMed

M. Negishi, H. Shimizu, S. Okada et al., HODE stimulates cell proliferation and extracellular matrix synthesis in human mesangial cells via PPARgamma. Exp. Biol. Med. (Maywood) 229(10), 1053–1060 (2004)

F.Y. Chow, D.J. Nikolic-Paterson, F.Y. Ma et al., Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 50(2), 471–480 (2007)CrossRefPubMed

S. Kiyici, E. Erturk, F. Budak et al., Serum monocyte chemoattractant protein-1, monocyte adhesion molecules in type 1 diabetic patients with nephropathy. Arch. Med. Res. 37(8), 998–1003 (2006)CrossRefPubMed

F.Y. Chow, D.J. Nikolic-Paterson, E. Ozols et al., Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 69(1), 73–80 (2006)CrossRefPubMed

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197 (1997)

10.

N. Banba, T. Nakamura, M. Matsumura et al., Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 58(2), 684–690 (2000)CrossRefPubMed

11.

S. Kato, V.A. Luyckx, M. Ots et al., Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int. 56(3), 1037–1048 (1999)CrossRefPubMed

12.

J.C. Rice, J.S. Spence, D.L. Yetman, R.L. Safirstein, Monocyte chemoattractant protein-1 expression correlates with monocyte infiltration in the post-ischemic kidney. Ren. Fail. 24(6), 703–723 (2002)CrossRefPubMed

13.

E. Simeoni, M.M. Hoffmann, B.R. Winkelmann et al., Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and type 2 diabetes mellitus. Diabetologia 47(9), 1574–1580 (2004)CrossRefPubMed

14.

B. Zietz, C. Buchler, H. Herfarth et al., Caucasian patients with type 2 diabetes mellitus have elevated levels of monocyte chemoattractant protein-1 that are not influenced by the −2518 A → G promoter polymorphism. Diabetes. Obes. Metab. 7(5), 570–578 (2005)CrossRefPubMed

15.

H. Mori, Y. Kaneko, I. Narita et al., Monocyte chemoattractant protein-1 A-2518G gene polymorphism and renal survival of Japanese patients with immunoglobulin A nephropathy. Clin. Exp. Nephrol. 9(4), 297–303 (2005)CrossRefPubMed

16.

M. Tucci, E.V. Barnes, E.S. Sobel et al., Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum. 50(6), 1842–1849 (2004)CrossRefPubMed

17.

B.H. Rovin, L. Lu, R. Saxena, A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem. Biophys. Res. Commun. 259, 344–348 (1999)CrossRefPubMed

18.

B. Krüger, B. Schröppel, R. Ashkan, B. Marder, C. Zülke, B. Murphy et al., A monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J. Am. Soc. Nephrol. 13, 2585–2589 (2002)CrossRefPubMed

19.

J.-y. Moon, L. Jeong, S. Lee, K. Jeong, T. Lee, C.-G. Ihm, J. Suh, J. Kim, Y.-y. Jung, J.-H. Chung, Association of polymorphisms in monocyte chemoattractant protein-1 promoter with diabetic kidney failure in Korean patients with type 2 diabetes mellitus. J. Korean Med. Sci. 22, 810–814 (2007)CrossRefPubMed

Titel: Monocyte chemoattractant protein-1 (MCP-1) 2518G/A gene polymorphism in Turkish type 2 diabetes patients with nephropathy
verfasst von: M. Karadeniz
M. Erdogan
Sevki Cetinkalp
A. Berdeli
Z. Eroglu
A. G. Ozgen
Publikationsdatum: 01.06.2010
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2010
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-010-9342-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Monocyte chemoattractant protein-1 (MCP-1) 2518G/A gene polymorphism in Turkish type 2 diabetes patients with nephropathy

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

A novel SLC4A1 variant in an autosomal dominant distal renal tubular acidosis family with a severe phenotype

Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus

Preliminary biochemical characterization of the novel, non-AT1, non-AT2 angiotensin binding site from the rat brain

Exercise-induced nausea and vomiting: another sign and symptom of pheochromocytoma and paraganglioma

Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer

Analysis of thyroglobulin gene polymorphisms in patients with autoimmune thyroiditis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin